Locus Bioscience
  • Platforms
  • Programs
  • Manufacturing
  • Careers
  • About Us
  • Newsroom
Contact

Newsroom

Learn more about us in our featured news stories and insights into our work

News Press Releases Locus Insights

Posts pagination

1 2 3 … 10 Next
  • September 10, 2024

    Crispr-Enhanced Viruses Are Being Deployed Against UTIs

    Learn More
  • August 12, 2024

    Locus Biosciences Announces Positive Results from Part 1 of ELIMINATE Phase 2 Trial of the Engineered Bacteriophage Therapy LBP-EC01 Published in The Lancet Infectious Diseases

    Learn More
  • October 3, 2024

    Inside LOCUS AI – How the team uses artificial intelligence

    Learn More
  • September 9, 2024

    Phage Therapy’s Neglected Potential Is Finally Being Realized

    Learn More
  • February 1, 2024

    Antimicrobial Resistance: Multiple Threats, Multiple Responses

    Learn More
  • February 1, 2024

    Locus milestone unlocks more BARDA cash

    Learn More
  • January 26, 2024

    Locus Biosciences receives $23.9 million from BARDA for CRISPR-engineered therapy trial

    Learn More
  • January 26, 2024

    BARDA backs Locus phage therapy for resistant E coli

    Learn More
  • January 26, 2024

    Locus Biosciences Receives $23.9 Million Boost for Bacteriophage Therapy Advancement in UTI Treatment

    Learn More
  • January 26, 2024

    BARDA Funds Next Stage of CRISPR-Based Bacteriophage Therapy

    Learn More
  • Posts pagination

    1 2 3 4 … 10 Next

Media Inquiries


For all media inquiries, please contact
our public relations agency below

Contact Now
Locus Biosciences

Precision Medicines for Bacterial Infections
and Immunologic Diseases

Home

Platform

Programs

Manufacturing

Careers

About Us

Newsroom

Contact Us

Location

523 Davis Drive Suite 350
Morrisville NC 27560

Email

info@locus-bio.com

Linkedin

Linkedin

Twitter

Twitter

©Copyright 2025 Locus Biosciences, Inc. All rights reserved.

powered by wildfire